BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29110781)

  • 1. Cerebrospinal fluid in the dementias.
    Zetterberg H; Rohrer JD; Schott JM
    Handb Clin Neurol; 2017; 146():85-97. PubMed ID: 29110781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biomarkers in spinal fluid of patients with dementia].
    Skogseth RE; Fladby T; Mulugeta E; Aarsland D
    Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2235-8. PubMed ID: 22085948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Bibl M; Wiltfang J; Steinacker P; Ciesielczyk B; Neubert K; Trenkwalder C; Otto M
    Clin Chem Lab Med; 2006; 44(2):192-5. PubMed ID: 16475906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
    de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
    J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
    Brunnström H; Rawshani N; Zetterberg H; Blennow K; Minthon L; Passant U; Englund E
    Alzheimers Dement; 2010 Mar; 6(2):104-9. PubMed ID: 20298970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.
    Kanemaru K; Kameda N; Yamanouchi H
    Neurology; 2000 May; 54(9):1875-6. PubMed ID: 10802808
    [No Abstract]   [Full Text] [Related]  

  • 11. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of Alzheimer's biomarkers in cerebrospinal fluid in dementia with Lewy body.
    Bousiges O; Blanc F
    Geriatr Psychol Neuropsychiatr Vieil; 2018 Jun; 16(2):174-180. PubMed ID: 29877185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Frequent involvement of the amyloid pathway in prodromal dementia with Lewy bodies].
    Monge-Argiles JA; Monge-Garcia V; Gasparini-Berenguer R; Garcia-Perez C; Gabaldon-Torres L; Salas-Felipe J; Leiva-Santana C
    Rev Neurol; 2019 Aug; 69(3):89-93. PubMed ID: 31309997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia.
    Llorens F; Schmitz M; Karch A; Cramm M; Lange P; Gherib K; Varges D; Schmidt C; Zerr I; Stoeck K
    Alzheimers Dement; 2016 May; 12(5):577-89. PubMed ID: 26718584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia.
    Gloeckner SF; Meyne F; Wagner F; Heinemann U; Krasnianski A; Meissner B; Zerr I
    J Alzheimers Dis; 2008 May; 14(1):17-25. PubMed ID: 18525124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.
    Müller M; Claassen JA; Kuiperij HB; Verbeek MM
    J Alzheimers Dis; 2015; 46(3):605-9. PubMed ID: 25812850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.